Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with docetaxel and nedaplatin after cytoreductive surgery for advanced ovarian cancer
ChiCTR-OPN-17011968Phase 4Recruiting
- Sponsor
- Shaanxi Cancer Hospital
- Start
- Jul 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib, docetaxel and nedaplatin in ovarian cancer (2 arms), sponsored by Shaanxi Cancer Hospital. Primary endpoint: Time to progression. Started Jul 2017; status: recruiting.
02
Drugs
Rivoceranibdocetaxelnedaplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OPN-17011968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-17011968.